Introduction {#sec1}
============

Breast cancer is the most common cause of death in women worldwide. It accounts for 14% of the total cancer deaths \[[@cit0001]\]. Some risk factors have been recognised, such as overweight and obesity, lifestyle, history of reproduction, steroid hormone managements, genetic factors, marital status, age at menarche, and oral contraceptives \[[@cit0002]--[@cit0005]\].

The relationship between obesity and risk of breast cancer depends greatly on menopausal status. In premenopausal women, obesity has been correlated with decreased risk of breast cancer, whereas it is associated with increased risk of breast cancer in post-menopausal women \[[@cit0006]\].

Obesity induces chronic inflammation, which increases local and systemic levels of cytokines such as tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6). Moreover, adipose tissue is now known as an endocrine organ, besides its function as a storage site of excess energy obtained from food intake. It produces adipokines (leptin and adiponectin), which also activate chronic inflammation \[[@cit0007]\].

Leptin (LEP), the obese (ob) gene product, is a 167 amino acids peptide hormone with proinflammatory functions. Its N terminal region is essential for the biological activities and binding to the receptor \[[@cit0008]\]. It plays an important role in the control of metabolism, immune processes, growth differentiation, and oxidation of lipids \[[@cit0009]\]. Leptin may inhibit proapoptosis signalling pathways and stimulate the growth of mammary tumour through several mechanisms, for example up-regulation of anti-apoptotic genes and down-regulation of apoptosis \[[@cit0010]\].

Leptin mediates its central and peripheral effects by leptin receptors (LEPR) present on the cell surface. It can bind to six isoforms of leptin receptors (obR a to f). These six isoforms belong to type I cytokine receptors family \[[@cit0011]\]. They contain a long isoform (obRb), which has full intracellular signalling, four short isoforms (OB-Rs) with less biological activity, and one secretory isoform \[[@cit0011]--[@cit0013]\].

Several single-nucleotide polymorphisms have been found in the leptin and leptin receptor genes in human. For example, an A that is substituted to G (at nt 668) leading to conversion of a glutamine to an arginine at codon 223 in exon 6 (Q223R) of the LEPR gene coding for the extracellular region in all isoforms of LEPR. This polymorphism affects the function of the receptor and changes its signalling capacity, which is linked to high levels of circulating leptin \[[@cit0014]\].

Numerous studies have confirmed the association of LEPR Q223R gene polymorphism with body mass index, insulin resistance, and postmenopausal breast cancer \[[@cit0015]\].

Hence, the present study aims to assess the effect of LEPR Q223R polymorphisms on breast cancer risk in Egyptian females, and their relation to different stages.

Material and methods {#sec2}
====================

Subjects {#sec2.1}
--------

This study was carried out on two groups. The first patient group comprised of 48 breast cancer females (mean age 47.7 ±7.5 years; mean BMI 34.37 ±6.08 kg/m^2^) who were selected from the Oncology Centre (MUOC) at Mansoura University through 2014--2015. Informed consent was obtained from all individuals included in the study. Approval of the Local Ethics Committee of Mansoura University was obtained, with reference code MS/190.

The second control group consisted of 48 heathy subjects (mean age 43.5 ±9.2 years; mean BMI 27.28 ±3.52 kg/m^2^) with no family or personal history of cancer breast.

Subjects with non-adenocarcinoma epithelial tumours, non-epithelial tumours, Li fraumeni syndrome, or a history of ionising irradiation were excluded.

Methods {#sec2.2}
-------

Five millilitres of peripheral blood was collected from the antecubital vein of overnight fasted patients. Then 1 ml peripheral blood was collected in EDTA vacutainer tube from patients and controls for DNA extraction and restriction fragment length polymorphism (RFLP). 4 ml blood was added to polypropylene tubes with a stopper, left to clot for 20 minutes, and the resulting serum was further divided into three aliquots. The aliquots were kept at --20°C for other laboratory tests.

Liver function tests (SGPT, SGOT, albumin, and bilirubin) and kidney function tests (creatinine) were assessed spectrophotometrically using COBAS Integra 400 plus Roche Diagnostics Ltd. CH-6343 Rotkreuz Switzerland. Cholesterol was estimated by CHOD-POD liquid \[[@cit0016]\], triglycerides by GPO-POD liquid \[[@cit0017]\], and HDL by precipitating reagent \[[@cit0018]\]; all were supplied by SPINREACT, S.A./S.A.U. SPAIN. Indirect measurement of LDL cholesterol was performed using the Friedewald equation:

LDL-c (mg/dl) = TC (mg/dl) − HDL-c (mg/dl) − TG (mg/dl) / 5 \[[@cit0019]\].

The carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) were estimated by electrochemiluminescence immunoassay (ECLIA) using ELECSYS 2010 Roch Diagnostics, Germany. Leptin hormone was estimated by sandwich ELISA technique using DBC Leptin ELISA, Diagnostics Biochem Canada Inc., cat. No. CAN-L-4260 \[[@cit0020]\].

PCR-RFLP {#sec2.3}
--------

DNA was extracted from whole blood samples by G-spin™ Total DNA Extraction MiniKit (Intron biotechnology, [www.intronbio.com](http://www.intronbio.com)). LEPR Q223R gene polymorphism was determined by PCR-RFLP (polymerase chain reaction restriction fragment length polymorphism).

For amplification of the region Gln223Arg polymorphism, the following primer was used: forward primer, 5-d ACCC TTT AAG CTG GGT GTC CCAAATGA-3; reverse primer,5-d CTA GCAAATA TTTTT GTAA GCAA TT -3. PCR amplification was done using DreamTaq PCR Green Master Mix (2X) (cat. No. k1081, Lithuania, EU). DreamTaq PCR Master Mix (2X) was gently vortexed and briefly centrifuged after thawing. The reaction mixture of total volume (25 µl) contained 15 µl PCR Master Mix, 0.5 µl forward primer (100 pmol), 0.5 µl reverse primer (100 pmol), 5.0 µl extracted DNA (100 ng), and 4 µl nuclease-free water. The samples were gently vortexed and PCR was done using the thermal cycle (Biorad PTC-100 peltier, USA) \[[@cit0021]\].

The reaction mixture was heated to 94°C for five minutes, followed by 30 cycles each consisting of 60 seconds at 94°C (denaturation), 60 seconds at 55°C (annealing), 60 seconds at 72°C (extension), and a final seven-minute extension at 72°C.

The PCR product was digested with MspI (Thermoscientific Fast Digest, cat. No. FD 0014, Lithuania) \[[@cit0021]\]. The reaction mixture of total volume (50 µl) contained 23 µl nuclease-free water (\#R0581), 15 µl buffer, 10 µl PCR product, and 2 µl MspI restriction enzyme. The components were incubated at 37°C for five minutes. The digested products were separated by electrophoresis in 2% agarose gels with ethidium bromide. The PCR product (440 bp) with G allele was digested by MspI to two fragments (300 and 140 bp), whereas the PCR product with A allele could not be digested and yielded one fragment at 440 bp. So the homozygous GG giave two bands at 300 and 140 bp, homozygous AA giave one band at 440 bp, and the heterozygous GA gave three bands at 440, 300, and 140 bp.

Lanes 1, 3, 5 represent AA genotypes (440 bp), lanes 2, 6, 7, and 9 represent GA genotypes (440, 300, and 140 bp), and lanes 4 and 8 represent GG genotype (300 and 140 bp) ([Fig. 1](#f0001){ref-type="fig"}).

![PCR-RFLP with MspI restriction enzyme](WO-21-29660-g001){#f0001}

Statistical analysis {#sec2.4}
--------------------

Excel (Microsoft Office 2013) and SPSS version 20 (statistical package for social science) (SPSS, Inc., Chicago, IL) were used for statistical analysis. The χ^2^ test was used for assessing differences from Hardy-Weinberg equilibrium expectations. The associations between breast cancer and leptin receptor Q223R polymorphism were measured by odds ratio and their 95% confidence interval. N.B: *p* ≤ 0.05 is significant at confidence interval 95%.

Results {#sec3}
=======

Serum cholesterol, triglycerides, and LDL-cholesterol showed significantly higher concentrations in breast cancer patients when compared to control subjects (0.004, 0.003, 0.006, respectively). There were significant increases in the concentrations of CEA (*p* =0.004), CA15-3 (*p* \< 0.001), and leptin hormone (*p* \< 0.001) in BC patients in relation to their concentrations in control subjects ([Table 1](#t0001){ref-type="table"}).

###### 

Lipogram, CEA, CA15-3, and leptin hormone concentrations in all studied groups

  Parameter                Control (*n* = 48)   BC Patients (*n* = 48)   *p*                    
  ------------------------ -------------------- ------------------------ -------- ------------- -------------------------------------------
  Cholesterol (mg/dl)      154                  112--259                 203      98--384       0.004[\*](#tf1-1){ref-type="table-fn"}
  Triglycerides (mg/dl)    93.5                 49--290                  152      48--348       0.003[\*](#tf1-1){ref-type="table-fn"}
  HDL (mg/dl)              39.5                 34--45                   39       32--47        0.985
  LDL (mg/dl)              98.5                 64--204                  131      64--247       0.006[\*](#tf1-1){ref-type="table-fn"}
  CEA (ng/ml)              0.69                 0.3--1.8                 1.75     0.4--9.3      0.004[\*](#tf1-1){ref-type="table-fn"}
  CA 15-3 (U/ml)           7.38                 5.3--13.4                19.045   5--261.5      \< 0.001[\*](#tf1-1){ref-type="table-fn"}
  Leptin hormone (ng/ml)   54.15                30.4--67.8               121.3    30.3--202.8   \< 0.001[\*](#tf1-1){ref-type="table-fn"}

p \< 0.05 (statistically significant)

CEA and CA 15-3 showed significant differences between various BC stages; this significance was attributed to significant increases in CEA and CA15-3 in stage IV when compared to stage I (*p* = 0.002, 0.009, respectively); stage II (*p* = 0.002, 0.001, respectively), and stage III (*p* = 0.003, 0.043, respectively) ([Table 2](#t0002){ref-type="table"}).

###### 

Comparison between various BC stages regarding CEA, CA 15-3, and leptin hormone concentrations

  Parameter                BC Patients (*n* = 48)   *p*                                                                                 
  ------------------------ ------------------------ ------ ------- -------- ----- ------- -------- ------ ------ ------- ------ ------- ---------
  CEA (ng/ml)              0.815                    0.6    5.1     1.1      0.4   4.8     1.8      0.5    7.1    5.2     0.5    9.3     0.002\*
  CA 15-3 (U/ml)           16.935                   8.7    45.5    13.115   5     21.8    19.215   6.8    52.0   40.5    15.3   261.5   0.003\*
  Leptin hormone (ng/ml)   121.3                    54.1   150.4   114.5    90    175.6   112.25   76.1   201    154.3   30.3   202.8   0.325

P1 = comparison between stage I vs. stage II

P2 = comparison between stage I vs. stage III

P3 = comparison between stage I vs. stage IV

P4 = comparison between stage II vs. stage III

P5 = comparison between stage II vs. stage IV

P6 = comparison between stage III vs. stage IV

CEA: (P1 = 0.729, P2 = 0.106, P3 = 0.002, P4 = 0.073, P5 = 0.002, P6 = 0.003)

CA15-3: (P1 = 0.184, P2 = 0.707, P3 = 0.009, P4 = 0.106, P5 = 0.001, P6 = 0.043)

Leptin: (P1 = 0.260, P2 = 0.386, P3 = 0.043, P4 = 1, P5 = 0.386, P6 = 0.686)

AA genotype showed significantly higher frequency in BC patients when compared to control subjects, with higher risk of developing BC (*p* = 0.025, OR = 5.308, 95% CI: 1.082--26.040). As regard to AG, GG genotypes, and A, G alleles, there were no significant differences in frequency between breast cancer patients and controls without risk of breast cancer ([Table 3](#t0003){ref-type="table"}).

###### 

Distribution of Leptin Receptor Q223R (alleles and genotypes) in BC patients and healthy control subjects

  Parameter        Control (*n* = 48)   BC Patients (*n* = 48)   *p*   OR     95% CI                    
  ----------- ---- -------------------- ------------------------ ----- ------ --------- ------- ------- --------
  Genotypes   AA   2                    4.2                      9     18.8   0.025\*   5.308   1.082   26.040
              AG   24                   50.0                     15    31.3   0.061     0.455   0.198   1.045
              GG   22                   45.8                     24    50.0   0.683     1.182   0.530   2.634
  Alleles     A    28                   29.2                     33    34.4   0.438     0.786   0.427   1.446
              G    68                   70.8                     63    65.6                             

More advanced BC stages (stage III and IV) showed no significant change in frequency in leptin receptor Q223R genotypes and alleles when compared to stage I and II ([Table 4](#t0004){ref-type="table"}).

###### 

Distribution of Leptin Receptor Q223R (alleles and genotypes) in BC patients according to stages

  Parameter        BC stage I and II (*n* = 24)   BC stage III and VI (*n* = 24)   *p*   OR     95% CI                   
  ----------- ---- ------------------------------ -------------------------------- ----- ------ -------- ------- ------- -------
  Genotypes   AA   7                              29.2                             2     8.3    0.137    0.221   0.041   1.201
              AG   5                              20.8                             10    41.7   0.119    2.714   0.757   9.727
              GG   12                             50.0                             12    50.0   1        1       0.323   3.101
  Alleles     A    19                             39.6                             14    29.2   0.283    1.591   0.680   3.722
              G    29                             60.4                             34    70.8                            

There was significant association between BC pathologic types and leptin receptor Q223R genotypes (*p* = 0.009) because the frequency of GG leptin receptor Q223R genotype was significantly high in Paget disease ([Table 5](#t0005){ref-type="table"}).

###### 

Comparison of BC pathological types between different Leptin Receptor Q223R genotypes in all studied groups

  Parameter         BC patients (*n* = 48)   *p*                           
  ----------------- ------------------------ ------ --- ------ ---- ------ ---------
  IDC               6                        66.7   9   60.0   14   58.3   0.009\*
  ILC               3                        33.3   5   33.3   1    4.2    
  Paget's disease   0                        0      1   6.7    9    37.5   

IDC -- invasive ductal carcinoma; ILC -- invasive lobular carcinoma

Discussion {#sec4}
==========

Breast cancer is the most common cause of death in women. It accounts for 14% of the total cancer deaths \[[@cit0001]\].

Obesity is associated with a high incidence of many serious diseases, including cancer \[[@cit0022]\]. Obesity due to lifestyles and unhealthy diets raises the risk of cancer, and it is predicted as a bad prognostic factor among survivors of breast cancer. Many studies reported that obesity is accompanied with high death rates from all cancers \[[@cit0023]\]. However, the mechanism by which obesity can develop breast cancer remains unclear \[[@cit0024], [@cit0025]\].

In the present study cholesterol, triglycerides, and LDL-cholesterol showed significantly higher concentrations in breast cancer patients when compared to controls ([Table 1](#t0001){ref-type="table"}). These findings are in accordance with Abdelsalam *et al*. \[[@cit0026]\] and Florenza *et al*. \[[@cit0027]\], who found that lipid profiles were increased significantly in all stages of breast cancer.

Leptin reduces body overweight and decreases the obesity rate as it regulates appetite and size of adipose tissue \[[@cit0028]\]. Although obese individuals have high levels of plasmatic leptin, they cannot control appetite as a result of development of non-responsive hypothalamic stage for the regulation of appetite and energy expenditure \[[@cit0029]\].

In the present study leptin hormone showed significantly higher concentrations in BC patients when compared to control subjects (*p* \< 0.001). Conversely, leptin hormone did not show significant differences between various BC stages. These findings are concordant with the findings of Cleary *et al*. \[[@cit0030]\]; Tessitore *et al*. \[[@cit0031]\]; Han *et al*. \[[@cit0032]\]; Chen *et al*. \[[@cit0033]\]; Hou *et al*. \[[@cit0034]\]; Liu *et al.* \[[@cit0035]\] and Taaban *et al*. \[[@cit0036]\], who reported that the serum levels of leptin were significantly higher in breast cancer patients than in controls. This can be explained by the fact that the main component of human breast is adipose tissue, which is the chief site of leptin secretion. It has been reported that leptin has a role in mammary glands development \[[@cit0037]\]. In addition, cancerous cells present in the mammary gland overexpress OB-R and respond to leptin stimulus by increasing vascular endothelial growth factor and its receptor 2, proliferation, and survival \[[@cit0038]--[@cit0040]\].

However Mantzoros *et al*. \[[@cit0041]\], Coskun *et al*. \[[@cit0042]\], Sauter *et al*. \[[@cit0043]\], Stattin *et al.* \[[@cit0044]\] and Woo *et al*. \[[@cit0045]\] reported that there was no relationship between breast cancer and serum leptin levels in postmenopausal women. This conflict can be explained by the failure of control of some potential factors, such as food intake, which affect leptin concentrations.

In the present study CEA showed significantly higher concentrations in breast cancer patients when compared to controls (*p* = 0.004) ([Table 1](#t0001){ref-type="table"}). This finding is in acordance with the results of Samy *et al*. \[[@cit0046]\], who found that preoperative serum levels of CA15-3 and CEA were significantly higher in breast cancer patients compared with the levels of the control group, and these markers decreased after operation.

In the present study CA15-3 showed significantly higher concentrations in breast cancer patients in comparison to control subjects (*p* \< 0.001) ([Table 1](#t0001){ref-type="table"}); also, CEA and CA 15-3 showed significant differences between various BC stages. This significance was attributed to significant increases in CEA and CA15-3 in stage IV when compared to stage I (*p* = 0.002, 0.009, respectively), stage II (*p* = 0.002, 0.001, respectively), and stage III (*p* = 0.003, 0.043, respectively), This is in agreement with Hashim \[[@cit0047]\], who reported increased levels of CA15-3 in breast cancer patients, when compared to women with benign tumours and healthy controls, and this increase is associated with advanced stages.

Paracchini *et al.* \[[@cit0048]\] demonstrated that a specific phenotype characterised by morbid obesity was produced due to genetic mutations in the leptin gene and the LEPR gene. Several polymorphisms related to an obese phenotype have been recognised in humans in the leptin and LEPR gene \[[@cit0049]\].

In the present study, the frequency of AA genotype of LEPR gene Gln223Arg polymorphisms was significantly high in BC patients when compared to controls (*p* = 0.025).

In agreement with our results, Snoussi *et al*. \[[@cit0050]\] and Anuradha *et al*. \[[@cit0051]\] reported that increased risk and poor prognosis of breast carcinoma are associated with leptin and LEPR polymorphisms. Also, Han *et al*. \[[@cit0021]\] described that the GA/AA genotypes of the LEPR gene (Gln223Arg) in combination with elevated lipids and leptin play a major role in the progression of breast cancer.

In contrast to our results, some researchers confirmed no association between Gln223Arg polymorphisms in the LEPR gene and breast cancer \[[@cit0052]\]. These differences may be attributed to gene-gene interaction, racial differences, and environmental factors. Also, changes in environmental temperature and stress can affect the expression of leptin \[[@cit0053]\] and change the risk of breast cancer.

Moreover, no significant differences were found between different leptin receptor Q223R genotypes in BC stages (*p* \> 0.05 for each).

The frequency of Leptin Receptor Q223R genotypes and pathologic parameters (ER, PR, HER2, cancers stage) in breast cancer patients were not significantly associated \[[@cit0054]\], although our study shows significant association between breast cancer pathologic types and leptin receptor Q223R genotypes (*p* = 0.009). This is because the frequency of GG leptin receptor Q223R genotype was significantly high in Paget disease. Snoussi *et al*. \[[@cit0050]\] found that the LEPR 223G allele is accompanied by short survival and bad prognosis in breast cancer.

One limitation of our study is the higher BMI in patients than in controls, which may influence the leptin level, in addition to the role of cancer.

In conclusion, leptin hormone shows significantly higher concentrations in breast cancer patients when compared to controls. It did not show significant differences between various breast cancer stages. As regard to LEPR Q223R gene polymorphism, AA genotype frequency was significantly high in breast cancer patients when compared to controls, with higher risk of developing breast cancer. Otherwise, other genotypes and alleles show no significant differences between breast cancer patients and controls with no risk of breast cancer.
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